Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Accumulated Expenses (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Accumulated Expenses for 7 consecutive years, with $9.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 22.01% to $9.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.6 million, a 22.01% decrease, with the full-year FY2025 number at $9.6 million, down 22.01% from a year prior.
  • Accumulated Expenses was $9.6 million for Q4 2025 at Pliant Therapeutics, up from $8.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $20.3 million in Q3 2022 to a low of $4.7 million in Q1 2023.
  • A 5-year average of $9.4 million and a median of $8.3 million in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 307.79% in 2021, then crashed 61.13% in 2023.
  • Pliant Therapeutics' Accumulated Expenses stood at $6.1 million in 2021, then soared by 41.4% to $8.7 million in 2022, then grew by 18.03% to $10.2 million in 2023, then grew by 20.88% to $12.4 million in 2024, then dropped by 22.01% to $9.6 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Accumulated Expenses are $9.6 million (Q4 2025), $8.2 million (Q3 2025), and $7.2 million (Q2 2025).